ORM 1153
Alternative Names: ORM-1153Latest Information Update: 12 Dec 2025
At a glance
- Originator Orum Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Peptide-chain-release factor 3 degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 08 Dec 2025 Pharmacodynamics and adverse events data from a preclinical trial in Acute myeloid leukemia released by Orum Therapeutics
- 06 Dec 2025 Pharmacodynamics and adverse events data from a preclinical trial in Acute myeloid leukemia presented at 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
- 07 Nov 2025 Orum Therapeutics plans to submit IND in Haematological malignancies in the second half of 2026